Controlled Clinical Trials
DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 18, Number 1, 1997

RICHARD PETO, RORY COLLINS, DAVID SACKETT, JANET DARBYSHIRE, ABDEL BABIKER, MARC BUYSE, HELEN STEWART, MICHAEL BAUM, ARON GOLDHIRSCH, GIANNI BONADONNA, PINUCCIA VALAGUSSA, LARS RUTQVIST, DIANA ELBOURNE, CHRISTINA DAVIES, OTILIA DALESIO, MAHESH PARMAR, CATHERINE HILL, MICHAEL CLARKE, RICHARD GRAY, AND RICHARD DOLL
The Trials of Dr. Bernard Fisher: A European Perspective on an American Episode 1

JANET ADAMS, MYRNA SILVERMAN, DONALD MUSA, AND PAMELA PEELE
Recruiting Older Adults for Clinical Trials 14

S.D. WALTER, DEBORAH J. COOK, GORDON H. GUYATT, DEREK KING, AND SUSAN TROYAN FOR THE CANADIAN LUNG ONCOLOGY GROUP
Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need? 27

GERD ROSENKRANZ
Can We Reduce the Dose of a Vaccine? 43

JON E. BLOCK
Interpreting Studies of Exercise and Osteoporosis: A Call for Rigor 54

ANDRE BOUCKAERT AND RALPH CROTT
The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations 58

MARIKA IWANE, JOLIE PALENSKY, AND KATHRYN PLANTE
A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data 65

Book Reviews 84

Books Reviewed 90

Erratum 90

List of Reviewers 91

Design Paper
MIKKO SYVÄNNE, MARJA-RITTA TASKINEN, MARKKU S. NIEMINEN, VESA MANNINEN, Y. ANTERO KESÄNIEMI, AMOS PASTERNACK, JAMES W. NAWROCKI, HARRY HABER, AND M. HEIKKI FRICK
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery: The Rationale, Design, and Baseline Characteristics of the LOCAT Study 93

Volume 18, Number 2, 1997

ANDREW R. WILLAN, BERNIE J. O'BRIEN, AND DEBORAH J. COOK
Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy 121

LAURENCE S. FREEDMAN, MITCHELL H. GAIL, SYLVAN B. GREEN, AND DONALD K. CORLE FOR THE COMMIT RESEARCH GROUP
The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT) 131

TIINA HOKKANEN, ELINA HEMMINKI, PIRJO AALTO, MATTI HAKAMA, HEINI HUHTALA, MARJA JYLHÄ, SAKARI KARJALAINEN, AND RISTO TUIMALA
Patient Managed Clinical Trial 140

THEODORE G. KARRISON
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations 151

WENDY J. MACK, STANLEY P. AZEN, MELEANA DUNN, AND HOWARD N. HODIS
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials 168

LANCE A. WALLER
A Note on Harold S. Diehl, Randomization, and Clinical Trials 180

Software Review 184

Erratum 185

Volume 18, Number 3, 1997

BERNARD VRIJENS AND ELS GOETGHEBEUR
Comparing Compliance Patterns Between Randomized Treatments 187

JI ZHANG, HUI QUAN, JENNIFER NG, AND MICHAEL E. STEPANAVAGE
Some Statistical Methods for Multiple Endpoints in Clinical Trials 204

PETER C. O'BRIEN, AND NANCY L. GELLER
Interpreting Tests for Efficacy in Clinical Trials With Multiple Endpoints 222

KAREN SUCHANEK HUDMON, ROBERT M. CHAMBERLAIN, AND RALPH F. FRANKOWSKI
Outcomes of a Placebo Run-in Period in a Head and Neck Cancer Chemoprevention Trial 228

LISA J. MARTIN, GINA A. LOCKWOOD, ALAN R. KRISTAL, VALENTINA KRIUKOV, CAROLYN GREENBERG, ANN L. SHATUCK, AND NORMAN F. BOYD
Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes 241

NICOLE URBAN, CHARLES DRESCHER, RUTH ETZIONI, AND CHRIS COLBY
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening 251

Book Review 271

Letter to the Editor 274

Volume 18, Number 3S, 1997
Supplement

Letter from the President 1S

Calendar of Program 4S

Abstracts: Second Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics 41S

Author Index 191S

Volume 18, Number 4, 1997

Quality of Life in Comparative Cancer Clinical Trials

EDWARD L. KORN
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make a Difference? 275

CHARLES B. SCOTT
Quality-Adjusted Survival Analysis of Malignant Glioma Patients 277

JAMES E. HERNDON II, STEWART FLEISHMAN, MICHAEL P. KOSTY, AND MARK R. GREEN
A Longitudinal Study of Quality of Life in Advanced Non–Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931 286

DAVID MACHIN
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make a Difference? 301

SYLVAN B. GREEN
Does Assessment of Quality of Life in Comparative Cancer Trials Make a Difference? A Discussion 306

CAROL M. MOINPOUR
Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments? 311

Original Articles

PAUL L. CANNER, BRUCE THOMPSON, GENELL L. KNATTERUD, NANCY GELLER, LUCIEN CAMPEAU, AND DAVID ZUCKER
An Application of the Zucker-Wittes Modified Ratio Estimate Statistic in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial 318

LAURA C. LOVATO, KRISTIN HILL, STEPHANIE HERTERT, DONALD B. HUNNINGHAKE, AND JEFFREY L. PROBSTFIELD
Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography 328

Design Paper

HAROLD P. ADAMS, JR., ROBERT F. WOOLSON, WILLIAM R. CLARKE, PATRICIA H. DAVIS, BIRGITTE H. BENDIXEN, BETSY B. LOVE, PATRICIA A. WASEK, AND KARLA J. GRIMSMAN
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 358

Software Review 378

Letters to the Editor

LESLIE A. KALISH AND HENRY A. FELDMAN
Number of Phone Lines for Telephone Randomization 380

PETER A. LACHENBRUCH
The Odds Ratio 381

Volume 18, Number 5, 1997

THEODORE C. MORRISON, DENNIS R. WAHLGREN, MELBOURNE F. HOVELL, JOY ZAKARIAN, SUSAN BURKHAM-KREITNER, C. RICHARD HOFSTETTER, DONALD J. SLYMEN, KRISTEN KEATING, STERGIOS RUSSOS, AND JENNIFER A. JONES
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias 383

PETER PEDUZZI, SAM DONTA, AND MARIKA IWANE
A Review of the Design of Vaccine Efficacy Trials and a Proposal for the Design of the VA Cooperative Study of Active Immunotherapy of HIV Infection 397

ROBERT P. McMAHON, MYRON A. WACLAWIW, NANCY L. GELLER, FRANCA B. BARTON, MICHAEL L. TERRIN, AND DUANE R. BONDS
An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) 420

JOHN P.A. IOANNIDIS, JOSEPH C. CAPPELLERI, HENRY S. SACKS, AND JOSEPH LAU
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection 431

WEN-MIIN LIANG AND MORTON B. BROWN
A Median-Based Test Under Informative Dropout: The One-Sample Case 445

Book Reviews 460

Design Paper

PAUL P. GLASZIOU, R. JOHN SIMES, JANE HALL, AND CAM DONALDSON, ON BEHALF OF THE LIPID STUDY GROUP
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD 464

Volume 18, Number 6, 1997
Papers from the Eighth International Symposium on Long-Term Clinical Trials
Guest Editors: Salim Yusuf, Michael Gent, Genell Knatterud, and Michael Terrin

SALIM YUSUF, MICHAEL GENT, GENELL KNATTERUD, AND MICHAEL TERRIN
Introduction 477

Surgical and Device Trials

HENRY BUCHWALD
Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy 478

JOHN W. KIRKLIN, EUGENE H. BLACKSTONE, DAVID C. NAFTEL, AND MALCOLM E. TURNER
Influence of Study Goals on Study Design and Execution 488

Lifestyle Modification

MEIR STAMPFER
Observational Epidemiology Is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification 494

MICHAEL L. TERRIN
Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification 500

SYLVAN B. GREEN
The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification 506

GENELL L. KNATTERUD
DISCUSSION: Why Clinical Trials in the Evaluation of Life Style Evaluation? 514

Multiple Outcomes

CHRISTOPHER P. CANNON
Clinical Perspectives on the Use of Composite Endpoints 517

STUART J. POCOCK
Clinical Trials with Multiple Outcomes: A Statistical Perspective on their Design, Analysis, and Intrepretation 530

MICHAEL GENT
DISCUSSION: Some Issues in the Construction and Use of Clusters of Outcome Events 546

Secondary Endpoints

ROBERT T. O'NEILL
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance 550

C.E. DAVIS
Secondary Endpoints Can Be Validly Analyzed, Even if the Primary Endpoint Does Not Provide Clear Statistical Significance 557

ROSS L. PRENTICE
DISCUSSION: On the Role and Analysis of Secondary Outcomes in Clinical Trials 561

When Is the Evidence Compelling from Clinical Trials or their Meta-Analyses?

MARCUS D. FLATHER, MICHAEL E. FARKOUH, JANICE M. POGUE, AND SALIM YUSUF
Strengths and Limitations of Meta-Analysis: Larger Studies May Be More Reliable 568

JANICE M. POGUE AND SALIM YUSUF
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis 580

SALIM YUSUF
Meta-Analysis of Randomized Trials: Looking Back and Looking Ahead 594

Societal, Ethical and Regulatory Issues in Clinical Trials: When Are Clinical Trials of a Given Agent or Class of Agent vs. Placebo No Longer Appropriate or Feasible?

BARUCH A. BRODY
When Are Placebo-Controlled Trials No Longer Appropriate? 602

ROBERT J. TEMPLE
When Are Clinical Trials of a Given Agent vs. Placebo No Longer Appropriate or Feasible? 613

Approaches to Informed Consent

GIANNI TOGNONI AND ENRICO GERACI
Approaches to Informed Consent 621

SUSAN S. ELLENBERG
Informed Consent: Protection or Obstacle? Some Emerging Issues 628

Errors, Misunderstandings, and Fraud

DAVID L. DeMETS
Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence 637

ROBERT M. CALIFF, SHARON L. KARNASH, AND LYNN H. WOODLIEF
Developing Systems for Cost-Effective Auditing of Clinical Trials 651

GEORGE W. WILLIAMS
DISCUSSION: Errors, Misunderstandings, and Fraud 661

Volume 18 Author Index 667

Volume 18 Subject Index 669

Volume Contents